Average years of life lost due to breast and cervical cancer and the association with the marginalization index in Mexico in 2000 and 2010

Cervantes, Claudio Alberto Dávila; Agudelo-Botero, Marcela

doi:10.1590/0102-311x00113813

Cited by 7 publications

(4 citation statements)

References 29 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45,46 Cervical cancer but also breast cancer are paradigm examples of complex regional cancer patterns, which are clearly linked to the level of deprivation. 47,48 In more developed areas breast cancer is more important than cervical while the opposite occurs in the more marginalized states of the country. [49][50][51][52] While the former is influenced by life style and nutritional risk factors the latter has an infectious background and lack of access to health services determinants.…”

Section: Discussionmentioning

confidence: 99%

The burden of cancer in Mexico, 1990-2013

et al. 2016

View full text Add to dashboard Cite

Objective. To analyze mortality and incidence for 28 cancers by deprivation status, age and sex from 1990 to 2013. Materials and methods. The data and methodological approaches provided by the Global Burden of Disease (GBD 2013) were used. Results. Trends from 1990 to 2013 show important changes in cancer epidemiology in Mexico. While some cancers show a decreasing trend in incidence and mortality (lung, cervical) others emerge as relevant health priorities (prostate, breast, stomach, colorectal and liver cancer). Age standardized incidence and mortality rates for all cancers are higher in the northern states while the central states show a decreasing trend in the mortality rate. The analysis show that infection related cancers like cervical or liver cancer play a bigger role in more deprived states and that cancers with risk factors related to lifestyle like colorectal cancer are more common in less marginalized states. Conclusions. The burden of cancer in Mexico shows complex regional patterns by age, sex, types of cancer and deprivation status. Creation of a national cancer registry is crucial.Keywords: cancer; burden of disease; mortality; incidence; social condition; cause of death; epidemiology ResumenObjetivo. Analizar la incidencia y la mortalidad de 28 tipos de cáncer por nivel de marginación, grupos de edad y sexo, de 1990 a 2013. Material y métodos. Los datos utilizados provienen del estudio de la Carga Global de Enfermedades (2013). Las entidades federativas se clasificaron de acuerdo con el índice de marginación del Consejo Nacional de Población. Resultados. Los datos muestran una tendencia decreciente para algunos cánceres (pulmón y cervical), mientras otros aparecen como prioritarios y relevantes (próstata, mama, estómago, colon e hígado). En el norte se observan incrementos regionales mayores en las tasas de incidencia y mortalidad estandarizadas por edad, mientras que en los estados del centro se observa una tendencia decreciente de la tasa de mortalidad. Conclusiones. La epidemiología del cáncer en México (en su mayoría basada en datos de mortalidad) presentan patrones regionales complejos por edad, sexo, tipo de cáncer e índice de marginación. Es vital la creación de un registro nacional para mejorar el seguimiento y evaluación de intervenciones preventivas y curativas.

show abstract

Section: Discussionmentioning

confidence: 99%

The burden of cancer in Mexico, 1990-2013

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The private sector consists of private pharmacies and health facilities where patients pay additional insurance contributions or out-of-pocket [21]. While several studies have investigated insurance coverage for breast, cervical and children cancer care in the public sector [23][24][25], there is scant research on the availability and affordability of cancer medicines.…”

Section: Introductionmentioning

confidence: 99%

Availability, prices, and affordability of selected essential cancer medicines in a middle-income country – the case of Mexico

Moye-Holz

Ewen

Dreser

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background: More alternatives have become available for the diagnosis and treatment of cancer in low-and middle-income countries. Because of increasing demands, governments are now facing a problem of limited affordability and availability of essential cancer medicines. Yet, precise information about the access to these medicines is limited, and the methodology is not very well developed. We assessed the availability and affordability of essential cancer medicines in Mexico, and compared their prices against those in other countries of the region. Methods: We surveyed 21 public hospitals and 19 private pharmacies in 8 states of Mexico. Data were collected on the availability and prices of 49 essential cancer medicines. Prices were compared against those in Chile, Peru, Brazil, Colombia and PAHO's Strategic Fund. Results: Of the various medicines, mean availability in public and private sector outlets was 61.2 and 67.5%, respectively. In the public sector, medicines covered by the public health insurance "People's Health Insurance" were more available. Only seven (public sector) and five (private sector) out of the 49 medicines were considered affordable. Public sector procurement prices were 41% lower than in other countries of the region. Conclusions: The availability of essential cancer medicines, in the public and private sector, falls below World Health Organization's 80% target. The affordability remains suboptimal as well. A national health insurance scheme could serve as a mechanism to improve access to cancer medicines in the public sector. Comprehensive pricing policies are warranted to improve the affordability of cancer medicines in the private sector.

show abstract

“…Nearly equal volumes of pharmaceuticals are consumed in the public and private sector [21,25]; however, 80% of pharmaceutical expenditure occurs in the private sector [26]. While several studies have investigated insurance coverage for breast, cervical and children cancer care in the public sector [23,27,28], there is scant research on the availability and affordability of cancer medicines.…”

Section: Introductionmentioning

confidence: 99%

Availability, prices, and affordability of selected essential cancer medicines in a middle-income country – the case of Mexico

Moye-Holz

Ewen

Dreser

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: More alternatives have become available for the diagnosis and treatment of cancer in low- and middle-income countries. Because of increasing demands, governments are now facing a problem of limited affordability and availability of essential cancer medicines. Yet, precise information about the access to these medicines is limited, and the methodology is not very well developed. Objective: To assess the availability and affordability of essential cancer medicines in Mexico, and compare their prices against those in other countries of the region. Methods: We surveyed 21 public hospitals and 19 private pharmacies in 8 states of Mexico. Data were collected on the availability and prices of 49 essential cancer medicines. Prices were compared against those in Chile, Peru, Brazil, Colombia and PAHO’s Strategic Fund. Results: Of the various medicines, mean availability in public and private sector outlets was 61.2% and 67.5%, respectively. In the public sector, medicines covered by the public health insurance “People’s Health Insurance” were more available. Only seven (public sector) and five (private sector) out of the 49 medicines were considered affordable. Public sector procurement prices were 41% lower than in other countries of the region. Conclusions: The availability of essential cancer medicines, in the public and private sector, falls below World Health Organization’s 80% target. The affordability remains suboptimal as well. A national health insurance scheme could serve as a mechanism to improve access to cancer medicines in the public sector. Comprehensive pricing policies are warranted to improve the affordability of cancer medicines in the private sector.

show abstract

Average years of life lost due to breast and cervical cancer and the association with the marginalization index in Mexico in 2000 and 2010

Abstract: Abstract

Cited by 7 publications

References 29 publications

The burden of cancer in Mexico, 1990-2013

The burden of cancer in Mexico, 1990-2013

Availability, prices, and affordability of selected essential cancer medicines in a middle-income country – the case of Mexico

Availability, prices, and affordability of selected essential cancer medicines in a middle-income country – the case of Mexico

Contact Info

Product

Resources

About